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BCL-2 family proteins regulate the mitochondrial apoptotic pathway.
BOK, a multidomain BCL-2 family protein, is generally believed to be
an adaptor protein similar to BAK and BAX, regulating the mito-
chondrial permeability transition during apoptosis. Here we report
that BOK is a positive regulator of a key enzyme involved in uridine
biosynthesis; namely, uridine monophosphate synthetase (UMPS).
Our data suggest that BOK expression enhances UMPS activity, cell
proliferation, and chemosensitivity. Genetic deletion of Bok results in
chemoresistance to 5-fluorouracil (5-FU) in different cell lines and in
mice. Conversely, cancer cells and primary tissues that acquire resis-
tance to 5-FU down-regulate BOK expression. Furthermore, we also
provide evidence for a role for BOK in nucleotide metabolism and
cell cycle regulation. Our results have implications in developing BOK
as a biomarker for 5-FU resistance and have the potential for the
development of BOK-mimetics for sensitizing 5-FU-resistant cancers.
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In metazoans, the intrinsic or mitochondrial apoptosis pathwayis regulated by the BCL-2 family of proteins. Among the dif-
ferent classes of the BCL-2 family proteins, the BH3-only pro-
teins act as the sentinels of cell death response. These proteins
act either directly to promote cell death, by activating the
adaptor proteins BAX and BAK at the mitochondrial surface, or
indirectly by displacing the inhibitory multidomain anti-apoptotic
BCL-2 family proteins from BAX and BAK, allowing the latter
to oligomerize and form pores on the mitochondrial membrane,
leading to apoptosis (1).
The function and regulation of most mammalian BCL-2 family
proteins have been well characterized, with the exception of
BOK. BOK was identified in a yeast 2-hybrid screen, using the
BCL-2 family member MCL-1 as the bait (2). When ectopically
overexpressed, BOK seems to act as a proapoptotic protein, and
its expression seemed to be restricted to reproductive tissues
such as ovaries (2). Subsequent studies have reported BOK ho-
mologs in flies and birds, confirming it as a member of the BCL-2
family protein, based on its conserved BH domains (3). BOK has
been reported to have various functions other than apoptosis,
such as its role in IP3R stability, as a neuroprotective factor
during seizure-induced neuronal injury (4–6), and in autophagy
regulation through its effect on MCL-1-BECLIN interaction in
human placenta (7). However, deletion of this gene had minimal
impact on apoptosis, despite it having a very broad tissue ex-
pression pattern. Double-knockout Bok−/−: Bax−/− females dis-
played a subtle phenotype in oocytes (8), and the triple-knockout
Bok−/−: Bax−/−: Bak−/− mice had severe developmental abnor-
malities compared with the double-knockout mice (9). This led
to the conclusion that BOK, with its structural similarity to BAX
and BAK, could have overlapping/redundant functions (9).
To get an insight into the cellular function of BOK, we un-
dertook a yeast 2-hybrid screen, using mouse BOK (mBOK) as
bait to identify its interaction partners. Screening of a mouse
embryonic cDNA library identified the bifunctional enzyme uri-
dine monophosphate synthetase (UMPS) as an interacting part-
ner. In this study, we conduct a detailed characterization of this
interaction and its functional consequence. We provide sub-
stantive proof for BOK-UMPS interaction significantly increasing
UMPS enzyme activity. As a result, BOK regulates uridine me-
tabolism, cell proliferation, and chemoconversion of 5-fluorouracil
(5-FU), a widely used drug used in adjuvant chemotherapy for
treating various types of cancers. We also report that BOK down-
regulation is a key feature in cell lines and patient-derived co-
lorectal cancer (CRC) cell organoids grown in culture, and pri-
mary CRC tissue samples that are resistant to 5-FU.
Significance
It is believed that the Bcl-2 family protein Bok has a redundant
role similar to Bax and Bak in regulating apoptosis. We report
that this protein interacts with the key enzyme involved in
uridine biosynthesis, uridine monophosphate synthetase, and
positively regulates uridine biosynthesis and chemoconversion
of 5-fluorouracil (5-FU). Bok-deficient cell lines are resistant to
5-FU. Bok down-regulation is a key feature of cell lines and
primary colorectal tumor tissues that are resistant to 5-FU. Our
data also show that through its impact on nucleotide metab-
olism, Bok regulates p53 level and cellular proliferation. Our
results have implications for developing Bok as a biomarker for
5-FU resistance and for the development of BOK mimetics for
sensitizing 5-FU-resistant cancers.
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BOK Interacts with UMPS through Its BH3 Domain. A yeast 2-hybrid
screening of a mouse embryonic library yielded a cDNA clone
that was identified as mouse UMPS (accession no. NM_009471.3).
The specificity of the interaction was confirmed in yeast interac-
tion with various nonspecific baits and with MCL-1 as a positive
control (Fig. 1A). This interaction was further confirmed at the
endogenous level by immunoprecipitation in mouse embryonic
fibroblasts (MEFs). Reciprocal immunoprecipitation of BOK or
UMPS confirmed the interaction, whereas Bok−/− cells did not
yield any interaction confirming the antibody specificity (Fig. 1B).
In lower forms of eukaryotes and in prokaryotes, the final 2
steps of de novo uridine biosynthesis are catalyzed by 2 enzymes
(i.e., orotate phosphoribosyltransferase [OPRTase], converting
orotate to orotidine monophosphate, and orotidine decarboxylase
[ODCase], which catalyses the decarboxylation of orotidine
monophosphate to uridine monophosphate [UMP]). In mammals,
these 2 steps are catalyzed by the bifunctional enzyme UMPS (10).
We conducted a deletion experiment in HEK 293T cells and
mapped the BOK interaction domain to be the ODCase domain
of UMPS. The OPRTase domain did not have any role in this
interaction (SI Appendix, Fig. S1 A and B). A previous study had
reported that the BH3 domain of BOK was crucial for its function
(11), and therefore, we tested whether the BH3 domain was im-
portant for UMPS-BOK interaction. Mutation in the conserved






Fig. 1. BOK interacts with UMPS through its BH3 domain. (A) Yeast 2 hybrid assay showing that BOK specifically interacts with UMPS. MCL-1 was used as a
positive control, whereas Uhx1, Pea 15, and FADD are used as negative controls. (B) Immunoprecipitation analysis of BOK-UMPS interaction in MEFs at physiological
levels of expression. (C) The BH3 domain of BOK mediates the interaction. Mutating the BH3 domain (BOK-AAA = L72A,R73A,L74A) abolishes the interaction (lane
2), and a chimeric BIMmutant with the BOK-BH3 domain could interact with the ODCase domain, whereas BIM by itself does not. (D) Confocal microscopy of MDCK
cells expressing GFP-tagged UMPS either with mCherry-tagged BOK-ΔBH3 (Top) or BOKWT (Bottom). (E) Molecular modeling of the BOK-BH3 domain docking on
ODCase. Cartoon diagram of BOK BH3 docked to ODCase dimer, viewed down the 2-fold symmetry axis (Top). Protein docking predictions place BOK (red) at the
dimer interface between α2b helices (Bottom) from both monomers (monomers are colored tan and khaki, respectively, with α2b helix axis in magenta).
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(Fig. 1C). This result was further corroborated by replacing the
BH3 domain of Bim (an intrinsically unstructured protein [12])
with that of Bok. Although Bim failed to interact with ODCase,
replacing the BH3 domain with that of BOK resulted in a strong
interaction (Fig. 1C), suggesting the BH3 domain is sufficient
in mediating the interaction between BOK and UMPS. We also
have confirmed this interaction by confocal microscopy (Fig.
1D). Molecular modeling suggests that the BOK BH3 domain
binds ODCase at the dimer interface (Fig. 1E). Conserved hy-
drophobic residues on BOK are predicted to interact with hy-
drophobic residues lining the surface of the ODCase dimer
interface (Fig. 1E).
BOK Regulates UMPS Activity and Chemosensitivity. In cancer cells,
UMPS is the enzyme primarily responsible for the conversion of
the chemotherapeutic drug 5-FU to its toxic metabolites (13).
Therefore, if BOK interaction regulates UMPS activity, that
should be manifested in the 5-FU response of Bok−/− cells. In
agreement with this, Bok−/− MEFs were resistant to 5-FU com-
pared with wild-type (WT) controls (SI Appendix, Fig. S2A). The
5-FU sensitivity in the WT MEFs could be reversed by the
pan-caspase inhibitor Q-VD-OPh, suggesting that the toxicity
of 5-FU was mediated by apoptosis (SI Appendix, Fig. S2A).
Etoposide induced apoptosis equally in both WT and Bok−/−
MEFs, suggesting there was no generalized defect in the apo-
ptotic pathway in Bok−/− MEFs. Human colorectal cancer cell
lines with CRISPR/Cas9 deletion of Bok consistently showed
resistance to 5-FU (SI Appendix, Fig. S2B). Similarly, treating
Bok−/− mice with 5-FU resulted in significantly reduced cell
death in the colon epithelium compared with WT mice (SI Ap-
pendix, Fig. S2C).
The first step in the conversion of 5-FU to its toxic metabolites
(i.e., conversion of 5-FU to 5-FUMP) is catalyzed by OPRTase
(14). If the binding of BOK to the ODCase domain had any
impact on the UMPS enzyme activity on the whole, it would be
reflected in the relative sensitivity of WT and Bok−/− cells to one
of the downstream metabolites of 5-FU. Accordingly, treating
WT and Bok−/− LIM1215 CRC cells with 5-FdUMP, one of the
major metabolites of 5-FU (15), resulted in similar levels of apo-
ptotic cell death in both cell lines. Bok−/− LIM1215 cells were clearly
protected against 5-FU, confirming that the conversion of 5-FU to
5-FUMP was the bottleneck in 5-FU resistance seen in Bok−/− cells
(Fig. 2A). In agreement with these observations, metabolomic
analysis of 5-FU metabolites in WT and Bok−/− LIM1215 cells
revealed that there was a generalized reduction in 5-FU metabolites
in Bok−/− cells (Fig. 2B). All these results suggested that binding of
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Fig. 2. Conversion of 5-FU to its toxic metabolites is the bottleneck in BOK-dependent apoptosis. (A) In the schematic, conversion of 5-FU to 5-FUMP is the
step mediated by UMPS. Accordingly, Bok−/− LIM1215 clones (western blot) are resistant to 5-FU (Left), whereas they are equally sensitive to the 5-FU me-
tabolite 5-FdUMP (Right) compared with the BOK-proficient controls. Cell survival was measured 72 h posttreatment by annexin V/PI staining. (B) Metab-
olomic analyses of 5-FU (in the medium) and its metabolites (in the lysates) in LIM1215 cells. (C) Enzyme kinetics of UMPS in the presence and in the absence of
BOK coexpression in insect cells. The Western blot shows the relative levels of protein in the lysates used in the assay. (B and C) “Res” refers to in vitro
developed 5-FU-resistant cells; also see Fig. 3. Error bars ± SEM (n = 3), except in C (±SD, n = 4 for 5-FU and n = 2 for PBS control) and E (±SD, n > 10). *P ≤ 0.05;
**P ≤ 0.005.








BOK to UMPS positively regulates its activity. Consistent with this
supposition, we performed an in vitro UMPS assay using BOK and
UMPS expressed in insect cells, and found that for equivalent
amounts of UMPS, presence of BOK increased UMPS activity by
3-fold (Fig. 2C).
BOK Is a Marker of Chemoresistance. Our data indicate that BOK
status appears to be a major determinant of 5-FU resistance in
these knockout cell lines. To get a perspective on the role of
BOK in 5-FU resistance in CRCs, we generated 5-FU-resistant
CRC cell lines by iterative treatment with incremental doses of 5-
FU in cell culture. We generated 7 such cell lines, and intrigu-
ingly, Western blot analysis revealed that a vast majority of these
cell lines had lost BOK expression (Fig. 3A). Ectopic expression
of BOK restored 5-FU sensitivity in LIM1215 cells to a signifi-
cant extent, suggesting that 5-FU resistance in these cells is
mostly due to the lack of BOK expression (SI Appendix, Fig.
S3A). These cells had cross-resistance against oxaliplatin, but
were sensitive to topoisomerase I inhibitor irinotecan (SI Ap-
pendix, Fig. S3 B and C). Since etoposide and irinotecan are
topoisomerase inhibitors (16, 17) and oxaliplatin induces DNA
adducts (18), it is conceivable that these 5-FU-resistant cells may
have additional mutations affecting DNA repair pathways dif-
ferentially, independent of BOK status. Consistent with this
notion, BOK−/− cells were sensitive to oxaliplatin and had a ro-
bust p53 response, determined by a p53-GFP reporter (ref. 19
and SI Appendix, Fig. S3 D and E). The reduction in BOK was
also seen in 5-FU-resistant primary human colorectal tumor
samples and in samples grown in organoid cultures (Fig. 3 B and
C). The 5-FU-sensitive colorectal samples had varying levels of
BOK, suggesting that they may be at a transitional stage of de-
veloping resistance. The reduction in BOK protein was reflected
in the levels of Bok mRNA in 5-FU-resistant cells (Fig. 3A).
Promoter methylation is one of the means of silencing BOK
expression in nonsmall cell lung carcinoma (20); however, ana-
lyzing the BOK promoter by either bisulfite sequencing or high-
resolution melting did not reveal any correlation between the
promoter methylation status and 5-FU sensitivity/BOK mRNA
expression levels (SI Appendix, Fig. S4 A and B), consistent with
the report by Carberry et al. (21).
The 5-FU sensitivity in Bok−/− MEFs and in HeLa cells could
be restored by the ectopic expression of WT BOK, but not with
the BH3 domain mutant (LRL72-74 to AAA) form of BOK,
consistent with the interaction of BOK BH3 domain with UMPS
and regulation of its activity (SI Appendix, Fig. S3 F andG). Similar
to 5-FU, we also observed cytosine arabinoside (cytarabine) resis-
tance (AraC) in Bok−/− cells. Furthermore, CRISPR/Cas9-mediated
deletion of UMPS in MEFs led to resistance to AraC, similar to
their resistance to 5-FU (SI Appendix, Fig. S5 A–C), suggesting that
AraC resistance could be the result of BOK regulation of UMPS
activity. However, analyzing patient-derived, AraC-resistant acute
myeloid leukemia samples showed that there was a total down-
regulation of BOK in all acute myeloid leukemia samples,
irrespective of their AraC resistance status (SI Appendix, Fig. S5D).
The reason for this down-regulation is not known, but is consistent
with reports that BOKmay be acting as a tumor suppressor (20–22).
A role for the BOK/UMPS axis in AraC sensitivity could be rec-
onciled in light of the promiscuous nature of OPRTase for its
substrate recognition. It could be argued that cytarabine is a sur-
rogate substrate for OPRTase, and that the conversion of cytar-
abine to cytarabine phosphate is mediated by OPRTase (10, 23).
5-FU-Mediated p53 Induction and Genotoxic Stress Are BOK-
Dependent. The tumor suppressor p53 is a critical determinant
of sensitivity to the 5-FU metabolite 5-FdU (24). 5-FdU is a
thymidylate kinase inhibitor that leads to DNA damage and p53
activation (24). We therefore determined the p53 response to 5-
FU in WT and Bok−/− MEFs, using a GFP reporter fused with
p53 responsive elements from the Bbc3 (Puma) gene (19).
Treating WT cells with 5-FU resulted in a robust induction of the
reporter, while Bok−/− MEFs showed no induction, suggesting
that 5-FU-mediated p53 induction was BOK-dependent (Fig.
4A). Control experiments showed that the p53 pathway was in-
tact in both cell lines, as demonstrated by GFP reporter in-
duction on treatment with etoposide (Fig. 4A). Furthermore, 5-
FU-mediated DNA damage (as measured by phosphorylated
gamma histone 2 or H2A.X) could be enhanced in both WT and
Fig. 3. BOK is a marker of chemoresistance. (A) Analysis of various 5-FU sensitive (P or parental) and resistant (R) colorectal cancer cell lines (developed
in vitro) for BOK protein status by Western blot (Left) and the Bok mRNA status by droplet digital PCR (Right). (B) Analysis of 5-FU-sensitive and 5-FU-
resistant primary colorectal cancer tissues for BOK protein levels. WT and Bok−/− HEPG2 cells were used as the antibody control. (C ) Analysis of 5-FU-
sensitive and 5-FU-resistant colorectal cancer organoids for BOK protein levels. WT and Bok−/− HCT15 cells were used as the antibody control. Error bars ±
SEM (n = 3), *P ≤ 0.005.
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Bok−/− HCT116 cells by the ectopic expression of WT BOK, but
not with the BH3 domain mutant (SI Appendix, Fig. S6). In-
triguingly, the basal level p53-GFP was significantly higher in
Bok−/− MEFs (Fig. 4B), which was corroborated in Bok−/− liver
tissues by mRNA analyses and in BOK-depleted cell lines by
Western blot analyses (Fig. 4B). Consistent with the data that
nucleotide deficiency is a known inducer of genome instability
and p53 response (25), treating BOK-deficient cell lines with
nucleotides reversed this phenotype including p21 induction
(Fig. 4 C and D), further corroborating the role of the BOK-
UMPS axis in regulating nucleotide biosynthesis.
Role of BOK in Cellular Proliferation. Reduced cell proliferation in
Bok−/− cells has previously been reported (11). Defects in nu-
cleotide metabolism could lead to a decrease in cell proliferation
(26, 27); therefore, we tested whether this proliferation defect
could be reversed by nucleotide supplementation. As a control
cell line, we also used Umps−/− MEF cells in which the last 2
steps of the uridine biosynthetic pathway is blocked by the ge-
netic ablation. These cells can only survive with UMP supple-
mentation in the medium. The proliferation defect observed in
Bok−/− cells could be partially reversed by the addition of UMP
(SI Appendix, Fig. S7 A and B). We also tested this in the ura3
strain of Saccharomyces cerevisiae (ODCase deficient), in which
the auxotrophy was complemented by mouse UMPS. Coex-
pression of BOK in this strain increased cell proliferation sig-
nificantly compared with BIM (SI Appendix, Fig. S7C). This is
consistent with the previous report that the proliferation defect
in Bok−/− MEFs could be rescued by the ectopic expression of
WT BOK, but not with the BH3 domain mutant of BOK (11).
Finally, we compared the liver regeneration capacity of WT and
Bok−/− animals (since hepatocytes express high levels of BOK [28]
and hepatocytes rely on de novo synthesis of pyrimidine nucleo-
tides [29]) after tetrachloride-induced liver injury (30). The extent
of liver damage as assessed by AST/ALT ratio at day 2 after the
injection was not significantly different between the WT and
Bok−/− mice (SI Appendix, Fig. S8), yet liver regeneration as ob-
served by histology was significantly impaired in Bok−/− mice, with
liver sections showing significant patches of hepatocyte loss con-
sistent with proliferation defect (SI Appendix, Fig. S8).
Discussion
Since the discovery of BCL-2 function in apoptosis (31), the role
of BCL-2 family members in regulating this process is well
established. Understanding the dynamics of interaction between
various BCL-2 family members and its impact on the mito-
chondrial apoptotic pathway has led to the development of novel
cancer therapeutics (32). However, in recent years, some of the
family members have been reported to possess nonapoptotic/
noncell death roles as well. These include regulation of mito-
chondrial morphology (33), regulation of ATP synthesis (34),
regulation of calcium homeostasis in the endoplasmic reticulum
(35), and regulation of glucose and lipid metabolism (36). Un-
derstanding the structural basis of the interaction between the
proapoptotic BCL-2 family protein BAD and glucokinase led to
the development of BAD mimetics that have the potential as
new-generation glucokinase activators for treating type 2 di-
abetes (37). In the present study, we provide a very compelling
argument for a role for BOK in regulating uridine metabolism
and 5-FU resistance (SI Appendix, Fig. S9).
Since its discovery in 1957 by Charles Heidelberger, 5-FU has
been one of the most commonly used drugs in adjuvant thera-
pies. (It is on the World Health Organization’s List of Essential
Medicines, the most important medications needed in a basic
health system [38]). 5-FU is a widely used chemotherapeutic
agent that inhibits cancer cell growth and initiates apoptosis by
targeting thymidylate synthase, and by direct incorporation of 5-
FU metabolites into DNA and RNA. 5-FU-based chemotherapy
improves overall and disease-free survival of patients with co-
lorectal, breast, and aero-digestive cancers (39). The combina-
tion of 5-FU with other anticancer drugs such as irinotecan,
Tomudex, and oxaliplatin has improved response rates for ad-
vanced CRC from 40% to 50% (40). Despite these improve-
ments, there are <12% of patients with advanced CRC who have
received systemic 5-FU chemotherapy who are still alive after 2 y
(41). De novo and acquired chemoresistance is the major ob-
stacle for the success of 5-FU-based chemotherapy. Although
thymidylate synthase protein overexpression is a major 5-FU
resistance-inducing factor (42), high thymidylate synthase expres-
sion does not account for all nonresponding tumors in patients
with CRC treated with 5-FU (41). 5-FU sensitivity is also influ-
enced by expression levels of dihydropyrimidine dehydrogenase,
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Fig. 4. 5-FU-mediated p53 induction and genotoxic stress is BOK-dependent. (A) MEFs of various genotypes (as indicated) expressing a p53-GFP reporter
were treated with either 5-FU (50 μg/mL) or etoposide (1 μg/mL), and the readout (GFP induction) was measured 24 h later by FACS analysis. (B) Basal levels of
p53 were measured by the p53 reporter assay in MEFs (Left), RNA analysis in mouse liver samples (Right), and Western blot analysis (Bottom) in WT and their
Bok−/− counterparts. (C) The increase in the basal level of p53 in Bok−/− HCT116 cells could be reversed by culturing the cells in UMP and CMP (1 mM).
Nonspecific band (NS) is used as loading control. (D) The p53 transcriptional target p21 induction could be reversed by culturing the cells in UMP and CMP
(1 mM). Error bars ± SD, n = 3 (except for D, where error bars ± SEM, n = 3). *P ≤ 0.005.








the genetic status of p53, and DNA mismatch-repair genes (40).
The experimental and clinical data about the predictive value of
these factors are still quite controversial. In addition, the precise
molecular mechanisms of 5-FU chemoresistance in patients with
cancer are still largely unknown. In the present study, we provide a
significant amount of data arguing for the role of BOK in regu-
lating 5-FU resistance and how it could be affecting p53-mediated
apoptosis (Fig. 4). Our findings are consistent with a previous
study by Carberry et al. (21) that reported a global down-
regulation of BOK protein levels in CRC tissues, most of which
received 5-FU-based chemotherapy. This study also found that
higher BOK levels correlate with poor prognosis, which may ap-
pear to be counterintuitive. However, considering the role of BOK
in nucleotide metabolism, one would expect the tumors with low/
no BOK levels to be impaired in proliferation, as previously
reported (11). This is likely to put selection pressure on these
tumors to restore BOK expression with additional mutations in
the apoptotic pathway, particularly the p53-mediated apoptotic
response (SI Appendix, Fig. S9). Therefore, understanding the
structural basis of the interaction between UMPS and BOK may
aid in the development of small molecule “BOK mimetics” in
activating 5-FU sensitivity in cancers. Furthermore, profiling
cancer tissues for BOK levels may help in developing BOK as a
diagnostic marker for stratifying cancers for 5-FU sensitivity.
Regulation of uridine metabolism is the most significant pheno-
type observed thus far in Bok−/− cells. The phenotype observed in
the triple-knockout Bok−/−: Bax−/−: Bak−/−mice (9) should be seen
in the context of the present findings. BOK ablation could lead to
nucleotide deficiency and up-regulation of p53 and the cell cycle
regulator p21, as previously reported (11).
Materials and Methods
For organoid cultures, rectal and peritoneal cancer tissues were taken from
patients undergoing surgery at the Peter MacCallum Cancer Centre with
patient informed consent and approval by the Peter MacCallum Cancer
Centre Human Ethics committee (ethics #14/185 and #15/76, respectively).
These patients were receiving Folfox (folinic acid/5-FU/oxaliplatin) adjuvant
therapy. 5-FU resistance/sensitivity was tested immediately after growing
the organoids in culture. The protocol for organoid culture was reported
previously (43). Details of other methods, including cell culture conditions,
yeast 2-hybrid screen, protein and RNA analyses, CRISPR editing, methyl-
ation analyses, apoptosis and cell proliferation assays, fluorescence micros-
copy, animal experiments, patient samples, p53 transcriptional assay,
quantitative metabolomics, computer modeling of the structures, and sta-
tistical analyses are presented in SI Appendix, Materials and Methods.
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